Solventum (NYSE:SOLV) Price Target Lowered to $70.00 at Wells Fargo & Company

Solventum (NYSE:SOLV) had its target price reduced by Wells Fargo & Company from $83.00 to $70.00 in a research note released on Wednesday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

A number of other research firms have also commented on SOLV. Piper Sandler reduced their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. KeyCorp raised their target price on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. BTIG Research reiterated a “buy” rating and set a $89.00 price target on shares of Solventum in a research report on Wednesday. Finally, Stifel Nicolaus increased their price objective on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and an average price target of $85.91.

Solventum Price Performance

Shares of Solventum stock opened at $70.91 on Wednesday. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The stock has a market capitalization of $12.30 billion, a price-to-earnings ratio of 8.69, a P/E/G ratio of 1.13 and a beta of 0.59. Solventum has a 1-year low of $62.38 and a 1-year high of $88.20. The firm’s 50-day moving average price is $67.88 and its two-hundred day moving average price is $74.51.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 24.03%. Solventum’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities analysts predict that Solventum will post 6.5 earnings per share for the current fiscal year.

Insider Transactions at Solventum

In other news, Director Amy Mcbride Wendell purchased 1,475 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the acquisition, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. The trade was a 41.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.24% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Nordea Investment Management AB lifted its stake in Solventum by 3.5% in the third quarter. Nordea Investment Management AB now owns 758,847 shares of the company’s stock valued at $54,880,000 after buying an additional 25,987 shares during the period. LSV Asset Management grew its position in shares of Solventum by 364.5% during the 3rd quarter. LSV Asset Management now owns 35,122 shares of the company’s stock worth $2,564,000 after buying an additional 27,561 shares during the period. Davis Selected Advisers grew its position in shares of Solventum by 0.5% during the 3rd quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock worth $402,786,000 after buying an additional 24,950 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Solventum by 15.3% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock valued at $22,469,000 after acquiring an additional 40,812 shares during the last quarter. Finally, Appleton Partners Inc. MA acquired a new stake in shares of Solventum in the 4th quarter valued at approximately $7,008,000.

More Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q1 beat on top- and bottom-line — SOLV reported $1.48 EPS vs. $1.35 est. and $2.01B revenue vs. $1.97B est.; organic sales rose 2.1%, helping justify the market’s positive reaction. Solventum Reports First Quarter 2026 Financial Results
• Positive Sentiment: Management reiterated FY2026 EPS guidance at $6.60 and said results are tracking toward the high end of the range, citing strong wound‑care and sterilization demand as a driver of higher profit expectations. Solventum forecasts annual profit at higher end on wound care demand
• Positive Sentiment: Earnings call flagged margin momentum ahead — management commentary and the slide deck highlighted margin improvement opportunities that investors view as supportive of 2026 profitability. Solventum Earnings Call Signals Margin Momentum Ahead
• Positive Sentiment: Technicals supportive in short term — SOLV recently cleared both the 20‑ and 50‑day moving averages, which traders interpret as a short‑term bullish signal. 20-day moving average breakout 50-day moving average breakout
• Neutral Sentiment: Mixed analyst stance — while BTIG reaffirmed a buy and $89 PT, consensus analyst stance remains around “hold,” leaving room for divergent reactions to news. BTIG reaffirmed buy / Benzinga summary Consensus recommendation: Hold
• Negative Sentiment: Tariff headwind flagged — management said tariffs could shave roughly $100M–$120M annually, a material drag on margins and free cash flow that tempers the upside from the beat. Tariff headwinds outlined
• Negative Sentiment: Wells Fargo cut the price target to $70 and moved to equal‑weight, signaling reduced near-term conviction and pressuring sentiment despite the beat. Wells Fargo price-target cut
• Negative Sentiment: Some commentary highlights margin pressure and pockets of sales decline that explain why the stock saw profit‑taking even after beats. Zacks: stock down despite beats

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.